Home / BUSINESS / Alembic Pharmaceuticals gains on reporting 23% rise in Q2 consolidated net profit

Alembic Pharmaceuticals gains on reporting 23% rise in Q2 consolidated net profit

Alembic Pharmaceuticals is currently trading at Rs. 548.05, up by 5.60 points or 1.03% from its previous closing of Rs. 542.45 on the BSE.

The scrip opened at Rs. 547.80 and has touched a high and low of Rs. 554.05 and Rs. 546.15 respectively. So far 806 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 636.50 on 03-Dec-2018 and a 52 week low of Rs. 435.10 on 21-Jun-2019.

Last one week high and low of the scrip stood at Rs. 562.00 and Rs. 531.45 respectively. The current market cap of the company is Rs. 10295.80 crore.

The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 15.97% and 11.06% respectively.

Alembic Pharmaceuticals has reported 7.02% rise in its net profit at Rs 268.69 crore for the quarter ended September 30, 2019 as compared to Rs 251.06 crore for the same quarter in the previous year. Total income of the company increased by 3.44% at Rs 1135.18 crore for Q2FY20 as compared Rs 1097.44 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 23.09% in its net profit at Rs 246.27 crore for the quarter under review as compared to Rs 200.07 crore for the same quarter in the previous year. Total income of the company increased by 9.90% at Rs 1241.23 crore for Q2FY20 as compared Rs 1129.43 crore for the corresponding quarter previous year.

Please share this news